Market Research Logo

Global Gonorrhea Therapeutics Market 2017-2021

Global Gonorrhea Therapeutics Market 2017-2021

About Gonorrhea Therapeutics

Gonorrhea is a sexually transmitted disease (STD) that affects both men and women. The infection affects the genitals, rectum, and the throat. The treatment landscape typically involves the use of antibiotics with dual therapy dominating the market compared with monotherapy. As the market has a deep penetration of generics, the growth rate is expected to be moderate during the forecast period. Additionally, the advent of new antibiotic-resistant strains will continue to hinder the growth prospects.

Technavio’s analysts forecast the global gonorrhea therapeutics market to grow at a CAGR of 2.88% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global gonorrhea therapeutics market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Gonorrhea Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Bharat Pharmaceuticals
  • GlaxoSmithKline
  • Merck
  • Pfizer
Other prominent vendors
  • Alopexx Pharmaceuticals
  • AstraZeneca
  • Cempra
  • Debiopharm Group
  • Melinta Therapeutics
Market driver
  • Rising prevalence of disease
  • For a full, detailed list, view our report
Market challenge
  • Emergence of antibiotic-resistant gonococcal strain
  • For a full, detailed list, view our report
Market trend
  • Advent of vaccine for prevention of gonorrhea
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?


Press Release

Technavio Announces the Publication of its Research Report – Global Gonorrhea Therapeutics Market 2017-2021

Technavio recognizes the following companies as the key players in the global gonorrhea therapeutics market: Bharat Pharmaceuticals, GlaxoSmithKline, Merck, and Pfizer

Other Prominent Vendors in the market are: Alopexx Pharmaceuticals, AstraZeneca, Cempra, Debiopharm Group, and Melinta Therapeutics.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is Advent of vaccine for prevention of gonorrhea . Gonorrhea is a major public health concern globally. It is considerably affecting the reproductive health of people and increasing the spread of human immunodeficiency virus (HIV). The currently available treatment regimen is unsuccessful in controlling the spread of Neisseria gonorrhoeae due to the rapid emergence of the antibiotic-resistant strains of this bacterium. Therefore, the prevention of the disease seems to be a more appropriate approach for controlling the spread of Neisseria gonorrhoeae.”

According to the report, one of the major drivers for this market is Rising prevalence of disease. The rising prevalence of gonorrhea is a major health concern globally. As per the CDC, approximately 700,000 new cases of gonorrhea are identified each year in the US. In 2009, the CDC reported 301,174 cases of gonorrhea, demonstrating an incidence rate of 99.1 cases per 100,000 US population. The disease follows chlamydial infection as the second most common STD in the US. The rising prevalence rate of gonorrhea is due to several factors such as growing awareness, increased healthcare access, availability of diagnostic tests, resistance patterns, reporting practices, and the financial constraints that limit the abilities of public healthcare officials to check the disease pattern precisely.

Further, the report states that one of the major factors hindering the growth of this market is Emergence of antibiotic-resistant gonococcal strain. The global gonorrhea therapeutics market is familiar with antibiotic resistance in gonorrheal strains. In 2007, the emergence of fluoroquinolone-resistant Neisseria gonorrhoeae prompted the CDC to prohibit the use of fluoroquinolone in the US, leaving cephalosporin as the only treatment option for gonorrheal infection. However, during 2006-2011, the minimum inhibitory concentration (MIC) of cefixime increased in the US and other countries, indicating the decrease in effectiveness of cefixime for treating the gonorrheal infection. In addition, these cefixime-resistant gonococcal strains are likely to develop tetracycline resistance but are susceptible to azithromycin.

Companies Mentioned

Bharat Pharmaceuticals, GlaxoSmithKline, Merck, Pfizer, Alopexx Pharmaceuticals, AstraZeneca, Cempra, Debiopharm Group, and Melinta Therapeutics.

  • Executive summary
  • Scope of the report
  • Research methodology
  • Introduction
    • Market outline
      • Table Incidence rate of gonorrhea in US, 2008 (per 100,000 population)
  • Gonorrhea: A brief introduction
    • What is gonorrhea?
    • What causes gonorrhea?
    • What are the various symptoms of gonorrhea?
      • Table Symptoms of gonorrhea
    • How is gonorrhea treated?
  • Market landscape
    • Market overview
      • Table Global gonorrhea therapeutics market: Snapshot
    • Market size and forecast
      • Table Global gonorrhea therapeutics market, 2016-2021 ($ millions)
      • Table Opportunity analysis of global gonorrhea therapeutics market
    • Five forces analysis
      • Table Five forces analysis
  • Pipeline
    • Table Key clinical trials
  • Market segmentation by application
    • Table Global gonorrhea therapeutics market: Segmentation by application
    • Table Global gonorrhea therapeutics market share by application, 2016
    • Monotherapy
    • Market size and forecast
      • Table Global gonorrhea monotherapy therapeutics market, 2016-2021 ($ millions)
    • Dual therapy
    • Market size and forecast
      • Table Global gonorrhea dual therapy therapeutics market, 2016-2021 ($ millions)
  • Regional landscape
    • Geographical segmentation
      • Table Global gonorrhea therapeutics market share by region, 2016 and 2021
      • Table Global gonorrhea therapeutics market revenue by region, 2016-2021 ($ millions)
      • Table Global gonorrhea therapeutics market share by region, 2016-2021
    • Regional comparison
      • Table Regional comparison
    • Americas - Market size and forecast
      • Table Gonorrhea therapeutics market in Americas 2016-2021 ($ millions)
    • EMEA - Market size and forecast
      • Table Gonorrhea therapeutics market in EMEA 2016-2021 ($ millions)
    • APAC - Market size and forecast
      • Table Gonorrhea therapeutics market in APAC 2016-2021 ($ millions)
    • Key leading countries
      • Table Key leading countries
      • Table Travel associated gonorrhea cases by region, 2008-2013
    • Market opportunity
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Prevalence rate of gonorrhea, 2009
      • Table Prevalence rate of gonorrhea by age and race
      • Table Infertility ratio in males and females
    • Market challenges
      • Table Revenue history for Zithromax/Zmax, 2005-2016
  • Market trends
    • Rising government initiatives to combat antibiotic resistance
    • Advent of vaccine for prevention of gonorrhea
    • Expedited Partner Therapy (EPT)
      • Table Pictorial presentation of EPT
  • Vendor landscape
    • Competitive landscape
      • Table Competitive structure analysis of global antibiotics market 2016
  • Key vendor analysis
    • Bharat Pharmaceuticals
      • Table Bharat Pharmaceuticals: Strength assessment
      • Table Bharat Pharmaceuticals: Strategy assessment
      • Table Bharat Pharmaceuticals: Opportunity assessment
    • GlaxoSmithKline
      • Table GlaxoSmithKline: Key highlights
      • Table GlaxoSmithKline: Strength assessment
      • Table GlaxoSmithKline: Strategy assessment
      • Table GlaxoSmithKline: Opportunity assessment
    • Merck
      • Table Merck: Key highlights
      • Table Merck: Strength assessment
      • Table Merck: Strategy assessment
      • Table Merck: Opportunity assessment
    • Pfizer
      • Table Pfizer: Key highlights
      • Table Pfizer: Strength assessment
      • Table Pfizer: Strategy assessment
      • Table Pfizer: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report